Targeted nanoparticles for treating resistant breast cancer
Formulation of a targeted nanoparticle system for the treatment of chemoresistant breast cancer
This study is testing a new way to deliver the chemotherapy drug doxorubicin directly to hard-to-treat breast cancer cells, hoping to make the treatment work better and cause fewer side effects for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Xavier University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project ID | NIH-10867375 on NIH RePORTER |
What this research studies
This research focuses on developing a specialized nanoparticle system designed to deliver the chemotherapy drug doxorubicin directly to chemoresistant breast cancer cells. By using an aptamer-labeled liposomal delivery method, the goal is to enhance the effectiveness of doxorubicin while reducing its harmful side effects on healthy tissues. The approach aims to overcome the challenges posed by multidrug resistance in cancer cells, which often limits the success of traditional chemotherapy. Patients may benefit from a more effective treatment option that minimizes toxicity and improves outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Her-2+ breast cancer who have shown resistance to standard chemotherapy treatments.
Not a fit: Patients with non-breast cancer types or those who do not have chemoresistant breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer treatment option for patients with chemoresistant breast cancer.
How similar studies have performed: Other research has shown promise in using targeted nanoparticle systems for cancer treatment, indicating a potential for success with this novel approach.
Where this research is happening
New Orleans, United States
- Xavier University of Louisiana — New Orleans, United States (Active)
Researchers
- Principal investigator: Kundu, Anup Kumer — Xavier University of Louisiana
- Study coordinator: Kundu, Anup Kumer
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.